candesartan has been researched along with Hyperglycemia in 7 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 1 diabetes was induced in rats by intraperitoneally injecting spontaneously hypertensive rats with streptozotocin." | 1.35 | Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats. ( Hayashi, K; Iigaya, K; Itoh, H; Kamayachi, T; Kumagai, H; Onami, T; Osaka, M; Sakata, K; Saruta, T; Takimoto, C, 2008) |
| "In candesartan-treated DM rats, UT-A3 increased in IM tip (160 +/- 14%) and base (210 +/- 19%)." | 1.35 | Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney. ( Blount, MA; Kent, KJ; Klein, JD; Price, SR; Sands, JM; Smith, TD, 2008) |
| " Ang II receptor type 1 blocker candesartan or ACE inhibitor captopril markedly attenuated eNOS-derived O(2)*(-) and hydrogen peroxide production while augmenting NO* bioavailability in diabetic aortas, implicating recoupling of eNOS." | 1.34 | Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. ( Cai, H; Oak, JH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kayano, R | 1 |
| Morofuji, Y | 1 |
| Nakagawa, S | 1 |
| Fukuda, S | 1 |
| Watanabe, D | 1 |
| Ozawa, H | 1 |
| Niwa, M | 1 |
| Matsuo, T | 1 |
| Takimoto, C | 1 |
| Kumagai, H | 1 |
| Osaka, M | 1 |
| Sakata, K | 1 |
| Onami, T | 1 |
| Kamayachi, T | 1 |
| Iigaya, K | 1 |
| Hayashi, K | 1 |
| Saruta, T | 1 |
| Itoh, H | 1 |
| Saitoh, Y | 1 |
| Hongwei, W | 1 |
| Ueno, H | 1 |
| Mizuta, M | 1 |
| Nakazato, M | 1 |
| Banes, AK | 1 |
| Shaw, S | 1 |
| Jenkins, J | 1 |
| Redd, H | 1 |
| Amiri, F | 1 |
| Pollock, DM | 1 |
| Marrero, MB | 1 |
| Oak, JH | 1 |
| Cai, H | 1 |
| Blount, MA | 1 |
| Sands, JM | 1 |
| Kent, KJ | 1 |
| Smith, TD | 1 |
| Price, SR | 1 |
| Klein, JD | 1 |
| Lansang, MC | 1 |
| Osei, SY | 1 |
| Coletti, C | 1 |
| Krupinski, J | 1 |
| Hollenberg, NK | 1 |
7 other studies available for candesartan and Hyperglycemia
| Article | Year |
|---|---|
In vitro analysis of drugs that improve hyperglycemia-induced blood-brain barrier dysfunction.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Barrier; Cilostazol; Disease Models, Animal | 2018 |
Candesartan and insulin reduce renal sympathetic nerve activity in hypertensive type 1 diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2008 |
Candesartan attenuates fatty acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2010 |
Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida | 2004 |
Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Captopril; Dia | 2007 |
Candesartan augments compensatory changes in medullary transport proteins in the diabetic rat kidney.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporin 2; Benzimidazoles; Biphenyl Compounds; D | 2008 |
Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antimetabolites; Benzimidazoles; Biphenyl Compoun | 2002 |